#lungcancer search results

Despite screening recommendations, only 16% of people who are eligible undergo #LungCancer screening. Moffitt’s mobile lung screening unit is working to reshape that narrative! 🫁 Learn more about upcoming events and screenings: moffitt.org/endeavor/archi…


Though evidence suggests asbestos-contaminated talc is linked to thoracic cancers, no such link exists for asbestos-free talc. See the #pressrelease for this #research by Boffetta et al. here: bit.ly/4u3uKSc #LungCancer

JTOonline's tweet image. Though evidence suggests asbestos-contaminated talc is linked to thoracic cancers, no such link exists for asbestos-free talc. See the #pressrelease for this #research by Boffetta et al. here: bit.ly/4u3uKSc

#LungCancer

Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert

youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert
youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert
youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert
youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert

"Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life." In #APieceofMyMind, a psychiatrist and residency program director reflects on an unexpected #LungCancer diagnosis. ja.ma/48OxHxC

JAMA_current's tweet image. "Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life." 

In #APieceofMyMind, a psychiatrist and residency program director reflects on an unexpected #LungCancer diagnosis. 

ja.ma/48OxHxC

A real-world data by Community Oncology Alliance found that patients with de novo metastatic #breastcancer and #lungcancer treated in independent #community_oncology practices had survival outcomes exceeding SEER benchmarks. healthandpharma.net/community-onco…

ONCOLife_HP's tweet image. A real-world data by Community Oncology Alliance found that patients with de novo metastatic #breastcancer and #lungcancer treated in independent #community_oncology practices had survival outcomes exceeding SEER benchmarks. 
healthandpharma.net/community-onco…

MRD detection is emerging to guide adjuvant therapy and monitor recurrence in early-stage NSCLC. Tan et al. offer a framework for its clinical implementation. Read more: bit.ly/4tQu3f0 #LungCancer #NSCLC

JTOonline's tweet image. MRD detection is emerging to guide adjuvant therapy and monitor recurrence in early-stage NSCLC. Tan et al. offer a framework for its clinical implementation. Read more: bit.ly/4tQu3f0

#LungCancer #NSCLC

Congratulations to the newly elected @ASCO #FASCO Recipients, who have excelled in their field and service to the organization. Special shot out to Dr Lyudmila Bazhenova @UCSDHealth for her leadership in the @asco 🫁 #lungcancer living guidelines

Latinamd's tweet image. Congratulations to the newly elected @ASCO #FASCO Recipients, who have excelled in their field and service to the organization.
Special shot out to Dr Lyudmila Bazhenova @UCSDHealth for her leadership in the @asco 🫁 #lungcancer living guidelines

#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart of @WilmotCancer, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

eaonc's tweet image. #ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart of @WilmotCancer, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

REGISTER HERE👉 buff.ly/gAk4CPg @COR2EDMedEd invites you to An upcoming virtual Experts Knowledge Share on the evolving TROP2-directed antibody drug conjugates (ADC) landscape in metastatic non-small cell #LungCancer ( #NSCLC ), and strategies to optimise the treatment

OncoAlert's tweet image. REGISTER HERE👉  buff.ly/gAk4CPg 
@COR2EDMedEd invites you to An upcoming virtual Experts Knowledge Share on the evolving TROP2-directed antibody drug conjugates (ADC) landscape in metastatic non-small cell #LungCancer ( #NSCLC ), and strategies to optimise the treatment

A lot's happening in #LungCancer and importantly, patients are benefiting! @christinemdmph & @JonVillenaMD joined me to talk about single-port robotic surgery, molecular testing & new Rxs. Learn about these & many more advances on @WeillCornell #CancerCast bit.ly/4mTjp4T


Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational

Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational
Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational
Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational
Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational

Congratulations to @FredrikThege & @SonjaWoermann for their @CellRepMed paper: An autochthonous CRISPR activation screening platform (FiCASCan) for characterizing tissue-specific oncogene selection in #PancreaticCancer & #LungCancer cell.com/cell-reports-m… #AACR26

Aiims1742's tweet image. Congratulations to @FredrikThege & @SonjaWoermann for their @CellRepMed paper: 
An autochthonous CRISPR activation screening platform (FiCASCan) for characterizing tissue-specific oncogene selection in #PancreaticCancer & #LungCancer
cell.com/cell-reports-m…
#AACR26

Radon is a quiet threat—but awareness starts with a single bookmark. Learn more about the Bookmark Project: lungcan.org/bookmark #RadonAwareness #LungCancer #BookmarkProject

LungCAN's tweet image. Radon is a quiet threat—but awareness starts with a single bookmark.

Learn more about the Bookmark Project: lungcan.org/bookmark

#RadonAwareness #LungCancer #BookmarkProject

#MPM26 #Lungcanceradvocacy in action at the 3rd Biennial Miami Precision Medicine Conference- #lungcancer survivors are a living proof of why #researchmatters #precisiononcology #biomakertesting in 🫁 cancer @lcfamerica @KRASKickers @EGFRResisters @Exon20Group @TheWRP4LC

Latinamd's tweet image. #MPM26 #Lungcanceradvocacy in action at the 3rd Biennial Miami Precision Medicine Conference- #lungcancer survivors are a living proof of why #researchmatters #precisiononcology #biomakertesting in 🫁 cancer  @lcfamerica @KRASKickers @EGFRResisters @Exon20Group @TheWRP4LC

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

PrECOGonc's tweet image. The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

Jellyfish sign 🪼 44M. 15 mm RML nodule. Biopsy → adenocarcinoma. 3 tags to costal pleura (green) + more tags to major fissure (red). Tags to >1 pleural surface = visceral pleural invasion until proven otherwise. Full case: ctchestreview.com/post06/ #ctchest #lungcancer

bhavinj's tweet image. Jellyfish sign 🪼
44M. 15 mm RML nodule. Biopsy → adenocarcinoma.
3 tags to costal pleura (green) + more tags to major fissure (red).
Tags to >1 pleural surface = visceral pleural invasion until proven otherwise.
Full case: ctchestreview.com/post06/
#ctchest #lungcancer

📈 Lung cancer survival is improving. 5-year survival has risen to ~27–28%, up from 15–17% in the 1990s—thanks in part to targeted therapies and immunotherapy: clinicaloncology.com/a/RDgBAA/t #LungCancer #Oncology

ClinOncNews's tweet image. 📈 Lung cancer survival is improving.
5-year survival has risen to ~27–28%, up from 15–17% in the 1990s—thanks in part to targeted therapies and immunotherapy: clinicaloncology.com/a/RDgBAA/t
#LungCancer #Oncology

Research presented by Mariana Do Carmo @yalepathology shows tumor suppressor gene loss plays a major role in how EGFR-mutant #lungcancer grows and responds to therapy. Certain gene losses can accelerate tumor growth or drive resistance to EGFR inhibitors. #AACR26 @AACR

YaleCancer's tweet image. Research presented by Mariana Do Carmo @yalepathology shows tumor suppressor gene loss plays a major role in how EGFR-mutant #lungcancer grows and responds to therapy. Certain gene losses can accelerate tumor growth or drive resistance to EGFR inhibitors. #AACR26 @AACR

The lung cancer community settled the IO-timing question for resectable disease over the past five years. What can HPV-negative head and neck cancer borrow? 5-post series, Parts 1-2 live. Link below. linkedin.com/feed/update/ur… #HNSCC #Immunotherapy #LungCancer #HPVNegative


Pesticide residue may play a role in increased rates of lung cancer in non-smokers under age 50. #LungCancer #CancerRisk #Pesticides cancerhealth.com/article/eating…


Despite screening recommendations, only 16% of people who are eligible undergo #LungCancer screening. Moffitt’s mobile lung screening unit is working to reshape that narrative! 🫁 Learn more about upcoming events and screenings: moffitt.org/endeavor/archi…


Though evidence suggests asbestos-contaminated talc is linked to thoracic cancers, no such link exists for asbestos-free talc. See the #pressrelease for this #research by Boffetta et al. here: bit.ly/4u3uKSc #LungCancer

JTOonline's tweet image. Though evidence suggests asbestos-contaminated talc is linked to thoracic cancers, no such link exists for asbestos-free talc. See the #pressrelease for this #research by Boffetta et al. here: bit.ly/4u3uKSc

#LungCancer

📈 Lung cancer survival is improving. 5-year survival has risen to ~27–28%, up from 15–17% in the 1990s—thanks in part to targeted therapies and immunotherapy: clinicaloncology.com/a/RDgBAA/t #LungCancer #Oncology

ClinOncNews's tweet image. 📈 Lung cancer survival is improving.
5-year survival has risen to ~27–28%, up from 15–17% in the 1990s—thanks in part to targeted therapies and immunotherapy: clinicaloncology.com/a/RDgBAA/t
#LungCancer #Oncology

Don’t wait to get screened. #LungCancer screening with low-dose CT (LDCT) takes less than 1 minute, no needles, no prep, and can help detect lung cancer early, when it’s more treatable. Find a screening center near you today: go2.org/lung-cancer/sc…


Mark my words when you end up in a psych ward with #psychosis or develop #lungcancer. Both are gruesome and can end a life sooner rather than later.


Radon is a quiet threat—but awareness starts with a single bookmark. Learn more about the Bookmark Project: lungcan.org/bookmark #RadonAwareness #LungCancer #BookmarkProject

LungCAN's tweet image. Radon is a quiet threat—but awareness starts with a single bookmark.

Learn more about the Bookmark Project: lungcan.org/bookmark

#RadonAwareness #LungCancer #BookmarkProject

It's #NationalCancerControlMonth. #DYK? 1 in 5 cancer deaths are due to lung cancer. It's important to know your risk factors and screening options for #LungCancer. Explore the Lung Cancer fact sheet to learn more: ow.ly/5K8k50YBTro #SWHRtalksCancer

SWHR's tweet image. It's #NationalCancerControlMonth. 
#DYK? 1 in 5 cancer deaths are due to lung cancer. It's important to know your risk factors and screening options for #LungCancer. 

Explore the Lung Cancer fact sheet to learn more: ow.ly/5K8k50YBTro #SWHRtalksCancer

Now presenting at #InnovationDublin: HEPTA Medical with CEO Thomas Bancel. HEPTA develops an incision-less microwave ablation platform delivering thermal energy via the airway to treat early-stage #lungcancer.

MedTechStrat's tweet image. Now presenting at #InnovationDublin: HEPTA Medical with CEO Thomas Bancel. HEPTA develops an incision-less microwave ablation platform delivering thermal energy via the airway to treat early-stage #lungcancer.
MedTechStrat's tweet image. Now presenting at #InnovationDublin: HEPTA Medical with CEO Thomas Bancel. HEPTA develops an incision-less microwave ablation platform delivering thermal energy via the airway to treat early-stage #lungcancer.

#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart of @WilmotCancer, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

eaonc's tweet image. #ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart of @WilmotCancer, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

The lung cancer community settled the IO-timing question for resectable disease over the past five years. What can HPV-negative head and neck cancer borrow? 5-post series, Parts 1-2 live. Link below. linkedin.com/feed/update/ur… #HNSCC #Immunotherapy #LungCancer #HPVNegative


🫁🌏 #LungCancer is the leading cause of cancer deaths worldwide, but with increased awareness and early detection, we can save lives. Learn more about how you can take action today: lcam.org/social-press-k… #LungCancerAwareness #EarlyDetectionSavesLives #LungHealth


Dr. Thomas Marron from @MountSinaiNYC explains why care partners are a vital member of the #lungcancer care team, from managing daily challenges to participating in appointments. Dr. Marron shares practical advice for care partners to stay involved: powerfulpatients.org/resource/care-…


Kudos to @JeffersonUniv for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

PrECOGonc's tweet image. Kudos to @JeffersonUniv for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

A real-world data by Community Oncology Alliance found that patients with de novo metastatic #breastcancer and #lungcancer treated in independent #community_oncology practices had survival outcomes exceeding SEER benchmarks. healthandpharma.net/community-onco…

ONCOLife_HP's tweet image. A real-world data by Community Oncology Alliance found that patients with de novo metastatic #breastcancer and #lungcancer treated in independent #community_oncology practices had survival outcomes exceeding SEER benchmarks. 
healthandpharma.net/community-onco…

A lot's happening in #LungCancer and importantly, patients are benefiting! @christinemdmph & @JonVillenaMD joined me to talk about single-port robotic surgery, molecular testing & new Rxs. Learn about these & many more advances on @WeillCornell #CancerCast bit.ly/4mTjp4T


📈 Lung cancer survival is on the rise! 5-year survival now ~27–28% vs 15–17% in the 1990s. Targeted therapy & immunotherapy are making a difference: clinicaloncology.com/a/RDgBAA/t #LungCancer #Oncology

ClinOncNews's tweet image. 📈 Lung cancer survival is on the rise! 5-year survival now ~27–28% vs 15–17% in the 1990s. Targeted therapy & immunotherapy are making a difference: clinicaloncology.com/a/RDgBAA/t #LungCancer #Oncology

🫁 As a partner in the @luciaeuproject, CNAG is hosting a project meeting of this EU-funded initiative focused on understanding lung cancer risk and improving early diagnosis Participants also visited our Sequencing Unit and Data Processing Centre #HorizonEurope #LungCancer

cnag_eu's tweet image. 🫁 As a partner in the @luciaeuproject, CNAG is hosting a project meeting of this EU-funded initiative focused on understanding lung cancer risk and improving early diagnosis

Participants also visited our Sequencing Unit and Data Processing Centre

#HorizonEurope #LungCancer

#LungCancer | Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement 👉 A case report 🔗journals.sagepub.com/share/SKJDZH2W…

TumoriJ's tweet image. #LungCancer | Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement 👉 A case report

🔗journals.sagepub.com/share/SKJDZH2W…

Join us in advancing thoracic malignancies care worldwide and improving survivorship, screening, staging, diagnostics, therapies and research in #lungcancer #cancers #Thoraciccancers @Intercancer @IASLC @myESMO @JCO_ASCO @JCOGO_ASCO @ASCO @JTOonline @CANCERKESHO @AORTIC_AFRICA

ChiteDoc's tweet image. Join us in advancing thoracic malignancies care worldwide and improving survivorship, screening, staging, diagnostics, therapies and research in #lungcancer #cancers #Thoraciccancers @Intercancer @IASLC @myESMO @JCO_ASCO @JCOGO_ASCO  @ASCO @JTOonline @CANCERKESHO @AORTIC_AFRICA

Hot off the press: Erasca’s pan-RAS drug ERAS-0015 shrank tumors in 62% of lung cancer patients and 40% of pancreatic cancer patients. Phase 1 data released today. statnews.com/2026/04/27/era… #KRAS #LungCancer #PancreaticCancer #CancerResearch #TCSC


Though evidence suggests asbestos-contaminated talc is linked to thoracic cancers, no such link exists for asbestos-free talc. See the #pressrelease for this #research by Boffetta et al. here: bit.ly/4u3uKSc #LungCancer

JTOonline's tweet image. Though evidence suggests asbestos-contaminated talc is linked to thoracic cancers, no such link exists for asbestos-free talc. See the #pressrelease for this #research by Boffetta et al. here: bit.ly/4u3uKSc

#LungCancer

Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert

youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert
youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert
youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert
youngkwangchae's tweet image. Great keynote lecture from Dr. @peters_solange at #ELCC2026 🎤. To avoid acquired resistance and prevent clonal divergence in #lungcancer 🫁, we need to deliver the most effective combination upfront 💥 and pursue ablation whenever possible 🔬. @myESMO @OncoAlert

Congratulations to the newly elected @ASCO #FASCO Recipients, who have excelled in their field and service to the organization. Special shot out to Dr Lyudmila Bazhenova @UCSDHealth for her leadership in the @asco 🫁 #lungcancer living guidelines

Latinamd's tweet image. Congratulations to the newly elected @ASCO #FASCO Recipients, who have excelled in their field and service to the organization.
Special shot out to Dr Lyudmila Bazhenova @UCSDHealth for her leadership in the @asco 🫁 #lungcancer living guidelines

MRD detection is emerging to guide adjuvant therapy and monitor recurrence in early-stage NSCLC. Tan et al. offer a framework for its clinical implementation. Read more: bit.ly/4tQu3f0 #LungCancer #NSCLC

JTOonline's tweet image. MRD detection is emerging to guide adjuvant therapy and monitor recurrence in early-stage NSCLC. Tan et al. offer a framework for its clinical implementation. Read more: bit.ly/4tQu3f0

#LungCancer #NSCLC

Congratulations to @FredrikThege & @SonjaWoermann for their @CellRepMed paper: An autochthonous CRISPR activation screening platform (FiCASCan) for characterizing tissue-specific oncogene selection in #PancreaticCancer & #LungCancer cell.com/cell-reports-m… #AACR26

Aiims1742's tweet image. Congratulations to @FredrikThege & @SonjaWoermann for their @CellRepMed paper: 
An autochthonous CRISPR activation screening platform (FiCASCan) for characterizing tissue-specific oncogene selection in #PancreaticCancer & #LungCancer
cell.com/cell-reports-m…
#AACR26

#MPM26 Fascinating talk by @VamsiVelcheti @MayoClinic on Early Cancer Detection using Machine Learning and AI for cancer therapeutic decision making in #lungcancer 👉🏽potential role of radiomics in understanding high-risk pulm nodules and early response to IO therapy #lcsm - at

Latinamd's tweet image. #MPM26 Fascinating talk by  @VamsiVelcheti @MayoClinic on Early Cancer Detection using Machine Learning and AI for cancer therapeutic decision making in #lungcancer 

👉🏽potential role of radiomics in understanding high-risk pulm nodules and early response to IO therapy #lcsm - at

Call me the Thoracic Oncology “Masters” ⛳️🏌️‍♀️ Today I received a special @TheMasters hat from a patient living with Stage IV EGFR #lungcancer—who checked off a bucket list dream of going to Augusta, GA to see it in person. I’m glad to have had a little part to play in this

Latinamd's tweet image. Call me the Thoracic Oncology “Masters” ⛳️🏌️‍♀️

Today I received a special @TheMasters hat from a patient living with Stage IV EGFR #lungcancer—who checked off a bucket list dream of going to Augusta, GA to see it in person.

I’m glad to have had a little part to play in this

Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational

Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational
Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational
Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational
Latinamd's tweet image. Great @umiamimedicine @SylvesterCancer surgical grand rounds this morning by @DoctorJSpicer @McGill, with a comprehensive overview of the evolution of perioperative therapy in resectable 🫁#lungcancer, along with practical advice for faculty launching careers in translational

#MPM26 #Lungcanceradvocacy in action at the 3rd Biennial Miami Precision Medicine Conference- #lungcancer survivors are a living proof of why #researchmatters #precisiononcology #biomakertesting in 🫁 cancer @lcfamerica @KRASKickers @EGFRResisters @Exon20Group @TheWRP4LC

Latinamd's tweet image. #MPM26 #Lungcanceradvocacy in action at the 3rd Biennial Miami Precision Medicine Conference- #lungcancer survivors are a living proof of why #researchmatters #precisiononcology #biomakertesting in 🫁 cancer  @lcfamerica @KRASKickers @EGFRResisters @Exon20Group @TheWRP4LC

Jellyfish sign 🪼 44M. 15 mm RML nodule. Biopsy → adenocarcinoma. 3 tags to costal pleura (green) + more tags to major fissure (red). Tags to >1 pleural surface = visceral pleural invasion until proven otherwise. Full case: ctchestreview.com/post06/ #ctchest #lungcancer

bhavinj's tweet image. Jellyfish sign 🪼
44M. 15 mm RML nodule. Biopsy → adenocarcinoma.
3 tags to costal pleura (green) + more tags to major fissure (red).
Tags to >1 pleural surface = visceral pleural invasion until proven otherwise.
Full case: ctchestreview.com/post06/
#ctchest #lungcancer

Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72) - ORR: 76% - Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response - New SoC #lcsm #LungCancer #OncTwitter

OncBrothers's tweet image. Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72)

- ORR: 76% 
- Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
- New SoC

#lcsm #LungCancer #OncTwitter
OncBrothers's tweet image. Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72)

- ORR: 76% 
- Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
- New SoC

#lcsm #LungCancer #OncTwitter
OncBrothers's tweet image. Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72)

- ORR: 76% 
- Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
- New SoC

#lcsm #LungCancer #OncTwitter
OncBrothers's tweet image. Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72)

- ORR: 76% 
- Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
- New SoC

#lcsm #LungCancer #OncTwitter

🫁 #ASCOAI: With gaps in molecular testing rates, #AI may expand access to clinical decision-making tools. Deep-learning models detected EGFR, ALK, BRAF, MET alterations in #lungcancer from H&E slides. 👨‍⚕️ Christian Rolfo, MD, PhD (@ChristianRolfo) #LCSM 🔗 ascoai.org/articles/2026/…

ASCOPost's tweet image. 🫁 #ASCOAI: With gaps in molecular testing rates, #AI may expand access to clinical decision-making tools.
Deep-learning models detected EGFR, ALK, BRAF, MET alterations in #lungcancer from H&E slides.
👨‍⚕️ Christian Rolfo, MD, PhD (@ChristianRolfo) #LCSM
🔗 ascoai.org/articles/2026/…

TIL therapy in NSCLC is advancing but smarter enrichment strategies could be the key to unlocking its full potential 🔬 @BenCreelan at #iwCART26 on how to optimise tumor-infiltrating lymphocytes for lung cancer #TILs #LungCancer

VJOncology's tweet image. TIL therapy in NSCLC is advancing but smarter enrichment strategies could be the key to unlocking its full potential 🔬 @BenCreelan at #iwCART26 on how to optimise tumor-infiltrating lymphocytes for lung cancer

#TILs #LungCancer

🫁 #AI is uncovering hidden misdiagnoses in #lungcancer (#LCSM) A study published in @JAMANetworkOpen found 3.1% of presumed lung squamous cell carcinomas were actually metastases. ➡️ Implications for treatment decisions are significant. 🔗 ascopost.com/news/march-202…

ASCOPost's tweet image. 🫁 #AI is uncovering hidden misdiagnoses in #lungcancer (#LCSM)
A study published in @JAMANetworkOpen found 3.1% of presumed lung squamous cell carcinomas were actually metastases.
➡️ Implications for treatment decisions are significant. 
🔗 ascopost.com/news/march-202…

REGISTER HERE👉 buff.ly/gAk4CPg @COR2EDMedEd invites you to An upcoming virtual Experts Knowledge Share on the evolving TROP2-directed antibody drug conjugates (ADC) landscape in metastatic non-small cell #LungCancer ( #NSCLC ), and strategies to optimise the treatment

OncoAlert's tweet image. REGISTER HERE👉  buff.ly/gAk4CPg 
@COR2EDMedEd invites you to An upcoming virtual Experts Knowledge Share on the evolving TROP2-directed antibody drug conjugates (ADC) landscape in metastatic non-small cell #LungCancer ( #NSCLC ), and strategies to optimise the treatment

🫁 Your body has a natural defense against lung cancer. What you eat can influence this. Green tea, turmeric, soy, broccoli, mushrooms, tomatoes, chili peppers, coffee, and cacao support this defense. #FoodAsMedicine #LungCancer #CancerResearch #Angiogenesis

drwilliamli's tweet image. 🫁 Your body has a natural defense against lung cancer.

What you eat can influence this.

Green tea, turmeric, soy, broccoli, mushrooms, tomatoes, chili peppers, coffee, and cacao support this defense.

#FoodAsMedicine #LungCancer #CancerResearch #Angiogenesis

1️⃣ -time low-dose CT screening for #lungcancer in a non–risk-based population can improve lung cancer mortality rates, study shows. Findings challenge current guidelines to risk-based screening. 🫁 Presented at #ELCC26; comments from @marinagarassino ascopost.com/news/april-202…

ASCOPost's tweet image. 1️⃣ -time low-dose CT screening for #lungcancer in a non–risk-based population can improve lung cancer mortality rates, study shows.
Findings challenge current guidelines to risk-based screening.
🫁 Presented at #ELCC26; comments from @marinagarassino
ascopost.com/news/april-202…

#Lungcancer spreads to the brain more than almost any other cancer. For many people living with it, that’s one of the most feared complications and until recently, one of the least understood. A new review just published in Science Signaling sets out what science is now

LungCancerEu's tweet image. #Lungcancer spreads to the brain more than almost any other cancer.

For many people living with it, that’s one of the most feared complications and until recently, one of the least understood.

A new review just published in Science Signaling sets out what science is now

Lung cancer screening programmes may have unexpected benefits beyond #lungcancer. A 🆕 study tracked 26K+ people through multiple screening rounds. Those whose scans flagged something unexpected were nearly 2X as likely to be diagnosed with a different cancer that year. The

LungCancerEu's tweet image. Lung cancer screening programmes may have unexpected benefits beyond #lungcancer.

A 🆕 study tracked 26K+ people through multiple screening rounds. Those whose scans flagged something unexpected were nearly 2X as likely to be diagnosed with a different cancer that year.

The

Participation in the Lung NODES National Quality Improvement Collaborative improved hospital-level compliance with lymph node sampling during #LungCancer surgery, with a median compliance increase from 67.8% to 90.5% across diverse program types. ja.ma/4tRj84E

JAMASurgery's tweet image. Participation in the Lung NODES National Quality Improvement Collaborative improved hospital-level compliance with lymph node sampling during #LungCancer surgery, with a median compliance increase from 67.8% to 90.5% across diverse program types. ja.ma/4tRj84E

Loading...

Something went wrong.


Something went wrong.